0001415889-22-008769.txt : 20220817 0001415889-22-008769.hdr.sgml : 20220817 20220817160650 ACCESSION NUMBER: 0001415889-22-008769 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220815 FILED AS OF DATE: 20220817 DATE AS OF CHANGE: 20220817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Marucci Anthony S CENTRAL INDEX KEY: 0001429933 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 221174041 MAIL ADDRESS: STREET 1: 66 COLD HILL DRIVE CITY: MENDAHM STATE: NJ ZIP: 07945 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 form4-08172022_010842.xml X0306 4 2022-08-15 0000744218 Celldex Therapeutics, Inc. CLDX 0001429933 Marucci Anthony S C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 true true false false PRESIDENT & CEO Common Stock 2022-08-15 4 M 0 75000 2.78 A 102692 D Common Stock 2022-08-15 4 M 0 45000 9.0165 A 147692 D Common Stock 2022-08-15 4 S 0 120000 37.6631 D 27692 D Incentive Stock Option 2.78 2022-08-15 4 M 0 75000 0 D 2029-06-19 Common Stock 75000 25000 D Incentive Stock Option 9.0165 2022-08-15 4 M 0 45000 0 D 2028-06-13 Common Stock 45000 26665 D Includes 461 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. This option was previously reported as covering 1,075,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the reverse stock split that occurred on February 8, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.39 to $37.95 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. As of June 13, 2022, the option is fully vested. /s/ Samuel B. Martin, attorney-in-fact for Anthony S. Marucci 2022-08-17